HIT! High Impact Clinical Trials 3

29 Mar 2026 14:10 15:10

Main Hall

In IgA Nephropathy

HeatherReich Moderator Canada

Sydney Tang Moderator Hong Kong, China

YusukeSuzuki Moderator Japan

Time	Session

14:10 14:20	Opening & Introduction Sydney Tang Speaker Hong Kong, China
14:20 14:32	Efficacy and Safety Results of Atrasentan in Patients With IgA Nephropathy on Sodium‚ äìglucose Co-transporter 2 Inhibitors: Phase II, Randomized, Placebo-controlled, Crossover Trial (Assist) HiddoLambers Heerspink Speaker Netherlands
14:32 14:35	Q&A
14:35 14:47	Efficacy and Safety of a Targeted-release Formulation of Budesonide (HR19042 Capsules) in Patients With Primary IgA Nephropathy: A Randomized, Double-blind, Multicenter, Placebo-controlled Phase 2/3 Trial XiaobingYang Speaker China
14:47 14:50	Q&A
14:50 15:02	Efficacy and Safety of Iptacopan in Patients With IgA Nephropathy (IgAN): Final 24-month Results From the Phase III APPLAUSE-IgAN Study VladoPerkovic Speaker Australia
15:02 15:05	Q&A
15:05 15:10	Closing Remarks